肿瘤乏氧放射增敏剂的研究进展  

Study Advances in Radiosensitizer for Tumor Hypoxia

作　　者：郭敏[1,2] 刘宏[1] 曹金发[1] 

机构地区：[1]广州军区武汉总医院药剂科,武汉430070 [2]湖北中医药大学药学院

出　　处：《中国药师》2015年第5期856-858,共3页China Pharmacist

摘　　要：改善肿瘤细胞的乏氧,可有效减少其对放疗的抵抗,从而提高治愈率。目前用于改善肿瘤细胞缺氧减少放射抵抗的化合物已经不仅仅局限于原有的亲电性放射增敏剂,许多具有靶向性的乏氧放射增敏剂也成为研究重点。本文在介绍肿瘤乏氧机制的基础上,对新型靶向制剂、亲电性乏氧细胞放射增敏剂、生物还原剂与植物天然提取物这四类乏氧细胞放射增敏剂的研究进展进行了综述。The improvement of hypoxia of tumor cells can effectively reduce their resistance to radiation and chemotherapy and im-prove the cure rate of the tumor. Recently, the compounds which are used to improve hypoxia of tumor cells and reduce radiation resist-ance are no longer just the original electrophilic radiosensitizers, and many potential targets as radiosensitizer for hypoxia also become research focus. Based on the mechanism of tumor hypoxia, the paper summarized the study progresses in four different radiosensitizers including new targeted agents, electrophilic radiotherapy sensitization agents, biological reductants and natural plant extracts.

关 键 词：肿瘤乏氧 放射增敏剂 乏氧诱导因子-1Α 研究进展 HIF-1Α 

分 类 号：R965.1[医药卫生—药理学]